Zepatier (elbasvir and grazoprevir) is a fixed-dose combination product containing a hepatitis C virus (HCV) NS5A inhibitor and an HCV NS3/4A protease inhibitor indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infections in adults.
The recommended dosage of it is one tablet taken orally once daily with or without food. It may interact with nafcillin, ketoconazole, bosentan, tacrolimus, HIV/AIDS medications, statin drugs, and modafinil. Tell your doctor all medications and supplements you use. During pregnancy, Zepatier should be taken only if prescribed. Its effects on a fetus are unknown. If Zepatier is administered with ribavirin, the combination regimen is not recommended in pregnant women and in men whose partners are pregnant. Consult your doctor. It is unknown if Zepatier passes into breast milk. If it is administered with ribavirin, the combination regimen is not recommended in nursing mothers. Consult your doctor before breastfeeding.